The most common form of bladder cancer is urothelial carcinoma, and it arises in cells that compose tubes in the kidneys and ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

Arnab Basu, MD, MPH, FACP, explains why sensitivity might be higher in urothelial cancer vs other genitourinary cancers.

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...

to be used as a monotherapy in treating adults with unresectable or metastatic urothelial carcinoma (UC), which is the most common form of bladder cancer (1,2). This approved indication specifically ...

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

While several molecular markers that are used to evaluate the development and prognosis of bladder cancer have been studied, the limited value of these established markers has created the need for ...

Opens in a new tab or window The indication for sacituzumab govitecan (Trodelvy) in previously treated patients with locally advanced or metastatic urothelial cancer was withdrawn last month after ...

Johnson & Johnson has announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved BALVERSA (erdafitinib) for treating adults with unresectable or metastatic ...

This study included a review of consecutive patients diagnosed with NMIBC between January 2005 and May 2023 to identify ...

In addition, the proportion of muscle-invasive bladder cancer was limited and ... value in locally advanced invasive or metastatic urothelial cancer.